Attack of the Drug Eaters
How does the gut microbiome influence the efficacy of Parkinson's medication?
Maryam Mahdi | | Quick Read
Research at Harvard University has shown that the commensal communities of bacteria in our gut are able to interfere with levodopa (L-dopa) – a commonly used medication in the treatment of Parkinson’s disease (PD) – thus highlighting a negative role of the microbiome in drug metabolism (1).
PD attacks neurons responsible for the production of the neurotransmitter dopamine. As this crucial chemical is lost, patients with the condition can suffer from symptoms, including tremors, speech changes and the rigidity of muscles.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.